Inhibrx, Inc. (NASDAQ:INBX – Get Free Report) CEO Mark Lappe purchased 26,963 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average price of $15.05 per share, for a total transaction of $405,793.15. Following the purchase, the chief executive officer now owns 692,511 shares in the company, valued at approximately $10,422,290.55. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Mark Lappe also recently made the following trade(s):
- On Monday, September 16th, Mark Lappe bought 13,037 shares of Inhibrx stock. The stock was purchased at an average cost of $17.13 per share, for a total transaction of $223,323.81.
- On Monday, September 9th, Mark Lappe acquired 9,500 shares of Inhibrx stock. The stock was purchased at an average cost of $15.21 per share, for a total transaction of $144,495.00.
- On Friday, September 6th, Mark Lappe purchased 26,000 shares of Inhibrx stock. The shares were acquired at an average cost of $15.29 per share, for a total transaction of $397,540.00.
- On Tuesday, September 3rd, Mark Lappe purchased 20,000 shares of Inhibrx stock. The stock was bought at an average price of $15.81 per share, with a total value of $316,200.00.
- On Thursday, August 29th, Mark Lappe bought 10,000 shares of Inhibrx stock. The shares were bought at an average price of $14.03 per share, with a total value of $140,300.00.
Inhibrx Stock Performance
NASDAQ INBX opened at $17.43 on Tuesday. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $18.95. The business has a fifty day moving average price of $13.71 and a two-hundred day moving average price of $23.60.
Analyst Ratings Changes
Separately, JMP Securities initiated coverage on shares of Inhibrx in a research report on Tuesday, July 23rd. They set a “market perform” rating for the company.
View Our Latest Report on Inhibrx
Institutional Trading of Inhibrx
A number of hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its position in Inhibrx by 8.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 229,866 shares of the company’s stock worth $8,735,000 after acquiring an additional 17,762 shares during the last quarter. Quadrant Capital Group LLC bought a new position in Inhibrx in the 4th quarter valued at approximately $26,000. HCR Wealth Advisors bought a new stake in Inhibrx during the 4th quarter worth approximately $239,000. Campbell & CO Investment Adviser LLC acquired a new position in Inhibrx in the 4th quarter valued at approximately $894,000. Finally, Vestal Point Capital LP bought a new position in shares of Inhibrx during the fourth quarter valued at $58,140,000. Institutional investors and hedge funds own 82.46% of the company’s stock.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Recommended Stories
- Five stocks we like better than Inhibrx
- What is Forex and How Does it Work?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- 3 Fintech Stocks With Good 2021 Prospects
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.